BioSpace News Archive

Diomics, a San Diego-based biotech company, today announced that it is currently developing the Diocheck™ Antibody Indicator, which provides a simple way for individuals to monitor for the presence of antibodies to SARS-CoV-2 over an extended period of time.

ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ:NDRA), the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced certain shareholders have confirmed the early exercise of approximately 7.1 million common stock warrants since July 1, 2020 for which ENDRA accepted reduced exercise prices

Researchers have modified a derivative of a plant toxin and linked it to a nanocarrier to create a powerful new therapeutic for childhood tumors. The new drug and its ability to eliminate chemoresistant tumors in mice is described in a new study published in Cancer Research, a journal of the American Association for Cancer Rese

Primary HLH is a family of devastating primary immune deficiencies with limited treatment options and no gene therapies under clinical testing. Expression Therapeutics has developed a promising and potentially curative gene therapy candidate for familial hemophagocytic lymphohistiocytosis (HLH) type 3 (FHL3). Untreated, FHL3 presents as a

CUTERA, INC., (Nasdaq: CUTR), a leading provider of laser, light and other energy-based aesthetic systems, today announced the launch of its new powerful Fraxis PRO progressive dermal remodeling technology.

FDA has Authorized Use of Antibody-Rich COVID-19 Therapy Derived from Convalescent Patients Under Collaboration BioBridge Global Will Be Using XBiotech’s COVID-19 Antibody Test to Identify the Convalescent Blood Products AUSTIN, Texas, Aug. 24, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for COVID-19 Convalescent Plasma (CCP) as a COVID-19 treatment, opening the door for

Nine presentations, including a long-term efficacy and safety analysis of DAYVIGO in adults ages 65 and older and interim results from a pilot study on the transition from zolpidem to DAYVIGO, to be shared at the meeting